These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38932865)

  • 1. Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis.
    Qazi SU; Ansari HUH; Tharwani ZH; Altaf Z; Noman A; Ghazanfar S; Kumar S; Ansari HW; Nasir MM; Qazi S
    J Diabetes Metab Disord; 2024 Jun; 23(1):405-415. PubMed ID: 38932865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Efpeglenatide in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
    Escobar J; Monday O; Vemoori Y; Yadav I; Maslamani ANJ; Al Kutabi S; Saeed L; Khan A
    Cureus; 2023 Sep; 15(9):e45927. PubMed ID: 37885518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.
    Frias JP; Choi J; Rosenstock J; Popescu L; Niemoeller E; Muehlen-Bartmer I; Baek S
    Diabetes Care; 2022 Jul; 45(7):1592-1600. PubMed ID: 35671039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.
    Pratley RE; Jacob S; Baek S; Trautmann ME; Hompesch M; Han O; Stewart J; Sorli CH; Shaunik A; Yoon KH
    BMJ Open Diabetes Res Care; 2022 Jan; 10(1):. PubMed ID: 35042751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials.
    Rangwala HS; Fatima H; Ali M; Mustafa MS; Shafique MA; Rangwala BS; Abbas SR
    J Diabetes Metab Disord; 2024 Jun; 23(1):1199-1222. PubMed ID: 38932909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
    Rosenstock J; Sorli CH; Trautmann ME; Morales C; Wendisch U; Dailey G; Hompesch M; Choi IY; Kang J; Stewart J; Yoon KH
    Diabetes Care; 2019 Sep; 42(9):1733-1741. PubMed ID: 31320446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
    Aroda VR; Frias JP; Ji L; Niemoeller E; Nguyên-Pascal ML; Denkel K; Espinasse M; Guo H; Baek S; Choi J; Lingvay I
    Diabetes Obes Metab; 2023 Aug; 25(8):2084-2095. PubMed ID: 37013892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis.
    Deng R; Mei K; Song T; Huang J; Wu Y; Yu P; Yan Z; Liu X
    Front Endocrinol (Lausanne); 2024; 15():1289643. PubMed ID: 38348420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis.
    Fatima H; Rangwala HS; Mustafa MS; Shafique MA; Abbas SR; Rizwan A; Fadlalla Ahmed TK; Arshad A
    Diabetes Metab Syndr Obes; 2023; 16():3567-3578. PubMed ID: 37954886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
    Del Prato S; Kang J; Trautmann ME; Stewart J; Sorli CH; Derwahl M; Soto A; Yoon KH
    Diabetes Obes Metab; 2020 Jul; 22(7):1176-1186. PubMed ID: 32128957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
    Pratley RE; Kang J; Trautmann ME; Hompesch M; Han O; Stewart J; Sorli CH; Jacob S; Yoon KH
    Diabetes Obes Metab; 2019 Nov; 21(11):2429-2439. PubMed ID: 31264757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
    Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
    Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
    Li WX; Gou JF; Tian JH; Yan X; Yang L
    Curr Ther Res Clin Exp; 2010 Aug; 71(4):211-38. PubMed ID: 24688145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roux-en-Y Gastric Bypass Versus Medical Treatment for Type 2 Diabetes Mellitus in Obese Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yan Y; Sha Y; Yao G; Wang S; Kong F; Liu H; Zhang G; Zhang H; Hu C; Zhang X
    Medicine (Baltimore); 2016 Apr; 95(17):e3462. PubMed ID: 27124041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
    Karakasis P; Patoulias D; Pamporis K; Stachteas P; Bougioukas KI; Klisic A; Fragakis N; Rizzo M
    Metabolism; 2023 Dec; 149():155710. PubMed ID: 37852529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.